Drug Action
Plerixafor is a chemokine receptor antagonist.
PDF page 1113
Loading InternPractice…
Drug reference
Plerixafor is a chemokine receptor antagonist.
PDF page 1113
Mobilise haematopoietic stem cells to peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma or multiple myeloma (specialist use only) ▶BY SUBCUTANEOUS INJECTION ▶Adult (body-weight up to 84 kg): 240 micrograms/kg daily, alternatively 20 mg daily usually for 2–4 days (and up to 7 days), to be administered 6–11 hours before initiation of apheresis, dose to be given following 4 days treatment with a granulocyte-colony stimulating factor; maximum 40 mg per day ▶Adult (body-weight 84 kg and above): 240 micrograms/kg daily usually for 2–4 days (and up to 7 days), to be administered 6–11 hours before initiation of apheresis, dose to be given following 4 days treatment with a granulocyte-colony stimulating factor; maximum 40 mg per day
PDF page 1113
Scottish Medicines Consortium (SMC) decisions SMC No. 594/09 The Scottish Medicines Consortium has advised (January 2010) that plerixafor (Mozobil ®) is accepted for use within NHS Scotland in combination with granulocyte-colony stimulating factor to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly. All Wales Medicines Strategy Group (AWMSG) decisions AWMSG No. 249 The All Wales Medicines Strategy Group has advised (April 2010) that plerixafor (Mozobil ®) is recommended as an option for restricted use within NHS Wales in combination with granulocyte-colony stimulating factor to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly. Plerixafor (Mozobil ®) should be restricted for use specifically in patients with non-Hodgkin’s lymphoma and multiple myeloma who have already failed one complete mobilisation attempt. The AWMSG is of the opinion that plerixafor (Mozobil ®) is not suitable for shared care within NHS Wales.
PDF page 1113
▶Common or very common Arthralgia. constipation. diarrhoea. dizziness. dry mouth. erythema. fatigue. flatulence. gastrointestinal discomfort. headache. hyperhidrosis. malaise. musculoskeletal pain. nausea. oral hypoaesthesia. sleep disorders. vomiting ▶Frequency not known Postural hypotension. splenomegaly . syncope
PDF page 1113
Use effective contraception during treatment— teratogenic in animal studies.
PDF page 1113
Manufacturer advises avoid unless essential— teratogenic in animal studies. Blood and nutrition
PDF page 1113
Manufacturer advises avoid—no information available.
PDF page 1113
No information available if creatinine clearance less than 20 mL/minute. Dose adjustments Manufacturer advises reduce dose to 160 micrograms/kg (maximum 27 mg) daily if creatinine clearance 20–50 mL/minute.
PDF page 1113
Monitor platelets and white blood cell count.
PDF page 1113
There can be variation in the licensing of different medicines containing the same drug. Solution for injection ▶Mozobil (Sanofi) Plerixafor 20 mg per 1 ml Mozobil 24mg/1.2ml solution for injection vials | 1 vial P £4,882.77 Platelet disorders 4.1 Essential thrombocythaemia Other drugs used for Essential thrombocythaemia Hydroxycarbamide, p. 985 ANTITHROMBOTIC DRUGS › CYCLIC AMP PHOSPHODIESTERASE III INHIBITORS
PDF pages 1113, 1114
Driving and skilled tasks Manufacturer advises patients and carers should be cautioned on the effects on driving and performance of skilled tasks—increased risk of dizziness, fatigue, or vasovagal reactions.
PDF page 1113
240 micrograms/kg
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1113
240 micrograms/kg
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1113